TNToscane C. Noordhoff

Toscane C. Noordhoff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Toscane C. Noordhoff has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Jeroen R. Scheepe

    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands

    6 shared publications
  • Bertil F. M. Blok

    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands

    4 shared publications
  • Bertil F.M. Blok

    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands

    2 shared publications
  • Lisette A. 'T Hoen

    Department of Urology Erasmus University Medical Center Rotterdam The Netherlands

    2 shared publications
  • Bertil Blok

    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands

    1 shared publication
  • Enrico Finazzi‐Agrò

    Department of Eperimental Medicine and Surgery, University of Rome "Tor Vergata", Urology Unit, Policlinico Tor Vergata, Rome, Italy

    1 shared publication

Latest Publications

  • Open Access

    Outcome and complications of adjustable continence therapy (ProACTTM) in the treatment of urinary incontinence after transurethral resection of the prostate: A multicenter study

    by Toscane C. Noordhoff, Enrico Finazzi‐Agrò, Jeroen R. Scheepe, Bertil F. M. Blok

    Aim: To evaluate the outcome of adjustable continence balloons in the treatment of stress urinary incontinence (SUI) after transurethral resection of the prostate (TURP).Methods: In two tertiary centers, adjustable continence balloons were implanted in 29 patients with post‐TURP SUI between 2007 and 2018. Endpoints of this retrospective multicenter study were patient‐reported changes in pad count and complications. Dry was defined as no pad or one security pad.Results: Preoperative urinary incontinence was mild in 7 (24%), moderate in 12 (41%), and severe in 10 (35%) patients. The median follow‐up duration was 21 (interquartile range [IQR], 11‐43) months. Within 30 days postoperatively, a Clavien‐Dindo grade less than or equal to II complication occurred in 24% of the patients. Reintervention rate was 24%. Six and 12 months after implantation, the International Prostate Symptom Score (IPSS) quality‐of‐life item improved significantly from 5 (IQR, 5‐6) preoperatively to 3 (IQR, 1‐4.5) and 1 (IQR, 0‐3), respectively. At last visit (median 21 months after implantation), the outcome on continence had improved in 76% of the patients, including, 45% dry patients. After a median follow‐up of 28 months (IQR, 13‐63; N = 23), all but one patient reported improvement on the Patient Global Impression of Improvement (PGI‐I) scale. In detail, 10 patients reported “very much better” condition compared with before the implantation, 10 patients “much better,” two patients “a little better,” and one patient “no change.” Daily pad use decreased from three (IQR, 2‐5) to one (IQR, 0‐2) pads/day (P < 0.001).Conclusions: This is hitherto, the first study reporting results of adjustable continence balloons in the treatment of post‐TURP SUI. The therapy was found to be safe and efficient. The majority of our study population reported improvement on their condition and greater than or equal to 50% reduction in daily pad use.


  • Long-term follow-up of bladder outlet procedures in children with neurogenic urinary incontinence

    by T.C. Noordhoff, J. van Den Hoek, M.J. Yska, K.P. Wolffenbuttel, B.F.M. Blok, J.R. Scheepe


  • Open Access

    The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15): Validation of the Dutch version in patients with multiple sclerosis and spinal cord injury

    by Toscane C. Noordhoff, Jeroen R. Scheepe, Lisette A. 'T Hoen, Tebbe A. R. Sluis, Bertil F. M. Blok

    AimsMethodsThe Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15) evaluates symptoms of sexual dysfunction in patients with multiple sclerosis (MS). The objective of this study was to provide and validate a Dutch version of the MSISQ-15 in patients with neurological disease such as MS and spinal cord injury (SCI). The linguistic validation process of the original English MSISQ-15 into Dutch was performed according to standardized guidelines. Sexually active patients with MS or spinal cord disorders, including SCI and cauda equine syndrome, who visited a tertiary urology center or a rehabilitation center completed the MSISQ-15, Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) in women, or International Index of Erection Function (IIEF-15) in men at baseline (test) and 2 weeks later (retest). A reference group recruited from a general medical practice completed the questionnaires once. Data were analyzed for measurement properties. ResultsConclusionsFifty-three patients with MS, 49 patients with spinal cord disorder, and 50 references were included. Content validity was adequate. Internal consistency (Cronbach's alpha >0.8) and reproducibility (intraclass correlation coefficient >0.8) of the MSISQ-15 were excellent. Patients' MSISQ-15 scores were correlated with severity of symptoms of sexual dysfunction measured by PISQ-12 or IIEF-15 and confirmed positive rating for criterion validity. MSISQ-15 scores in patients were higher than in references (on a scale of 15-75: 38.911.4 vs 21.1 +/- 5.4; P<0.001), indicating good construct validity. The Dutch MSISQ-15 is a reliable and valid measure to evaluate symptoms of sexual dysfunction in patients with MS or with SCI.


  • Open Access

    Tien jaar expertise met aanpasbare continentietherapie voor post-prostatectomie urine-incontinentie

    by Toscane C. Noordhoff, Jeroen R. Scheepe, Bertil F. M. Blok

  • Open Access

    Urotherapy in children with dysfunctional voiding and the responsiveness of two condition‐specific questionnaires

    by Toscane C. Noordhoff, Lisette A. 'T Hoen, Joop van Den Hoek, Jacintha T. C. M. Verhallen‐Dantuma, Marjan J. van Ledden‐Klok, Bertil F. M. Blok, Jeroen R. Scheepe

    Aims: We sought to establish the responsiveness of the Dutch Vancouver Symptom Score for Dysfunctional Elimination Syndrome (VSSDES) and Pediatric urinary incontinence Quality of life (PinQ) questionnaires. Secondary, we evaluated the outcome of urotherapy extended for children with dysfunctional voiding (DV).Methods: This cross‐sectional multicenter study was done in one tertiary and two community hospitals. Children with DV were included, also when refractory to previous urotherapeutic treatment. The questionnaires were completed before and after urotherapy. The primary outcome measure was the responsiveness of the Dutch VSDESS and PinQ. Secondary outcome was the initial success (defined by the International Children's Continence Society) of extended urotherapy.Results: Between June 2014 and May 2016, 64 children (median age 7 years, IQR 6‐10) received urotherapy (median 18 weeks, IQR 11‐28). In contrast to the VSSDES, the PinQ showed good responsiveness. For children and parents, respectively, the area under the ROC‐curve was 0.79 (P = 0.01) and 0.72 (P = 0.03) for the PinQ and 0.50 (P = 0.98) and 0.55 (P = 0.62) for the VSSDES. Fifty children received extended urotherapy, 27 had complete, and 14 had partial response. Sixteen children had been refractory to previous treatment; four showed complete, and six showed partial response.Conclusion: The PinQ is able to detect clinically important changes in continence‐specific quality of life after treatment. We support the use of the VSSDES questionnaire in addition to the current diagnostics for the diagnosis of DV. Extended urotherapy showed to be a successful treatment for children with DV, also for those who had received previous unsuccessful treatment.


  • Open Access

    Outcome and complications of adjustable continence therapy (ProACT™) after radical prostatectomy: 10 years’ experience in 143 patients

    by Toscane C. Noordhoff, Jeroen R. Scheepe, Bertil F.M. Blok

    Aims: To evaluate our outcomes of the adjustable continence balloons ProACT™ for the treatment of male stress urinary incontinence after radical prostatectomy.Methods: Between May 2007‐August 2016 the ProACT™ was implanted in 143 patients without a history of radiotherapy. Endpoints were patient‐reported changes in pad counts and complications. Treatment was considered successful if no pad or just one “security” pad per day sufficed, and improved if daily pad use was reduced by ≥50%.Results: Incontinence before implantation was mild in 36 (25%), moderate in 57 (40%), and severe in 50 (35%) patients. Complications within 30 days were classified by the Clavien‐Dindo classification; eight (5.6%) grade I, three (2.1%) grade II, three (2.1%) grade IIIb, and 129 (90.2%) patients had no complication. Revision was done in 43 (30%) patients. The IPSS quality of life item improved significantly from 5.0 (IQR 4.0‐5.0) preoperative to 2.0 (IQR 1.0‐4.0) and 1.0 (IQR 0.0‐3.0) 6 and 12 months after implantation, respectively. After a median follow up of 56 months (range 28 to 79, n = 112), 72 (64%) patients were improved, including 51 (45%) patients were successful. Daily pad use decreased from 3.0 to 1.0 (67% reduction). The median outcome on the Patient Global Impression of Improvement scale was “much better,” and 97 (87%) patients perceived improvement.Conclusions: The minimally invasive ProACT™ device showed a clear beneficial continence outcome in patients with stress urinary incontinence after radical prostatectomy. The majority of the patients were satisfied and perceived improvement ≥50% on daily pad use on the long term.